Table 1 Demographic details of the two different patient cohorts used for genotyping and gene expression studies.
From: Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action
| Â | 225 patients for ADORA polymorphisms | 20 patients for synovial gene expression |
|---|---|---|
Age (years) | 59.5 (18 to 84) | 66.4 (48 to 80) |
% Female | 72% | 90% |
Disease duration (years) | 10.4 (0.17 to 57) | 21.1 (3.7 to 47) |
Nodules | 56 (24.9%) | 12 (60%) |
Erosions | 139 (61.8%) | 19 (95%) |
RF +positive | 178 (79.1%) | 17 (85%) |
CCP positive | 165/214 (77.1%) | 11/15 (73.3%) |
Receiving MTX | 225 (100%) | 11 (55%) |
MTX dose (mean) (mg/wk) | 15.8 (5 to 25) | 16.4 (7.5 to 20) |
ESR | 16.6 (2 to 96) | 41.4 (14 to 74) (n = 10) |
CRP | 10.9 (0 to 150) | 18.9 (3 to 79) (n = 17) |
Anti-TNF therapy | 0 | 3 (15%) |
Prednisone | 71 (31.6%) | 6 (30%) |